TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22377563

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg daily for 28 days followed by 14 days off (arm 1)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily continuously (arm 2)
Number of subjects: 73
Study: 19324344

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18714110

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (pharmacist case manager providing admission medication verification, medication teaching, discharge counseling, faxing discharge care plan, follow-up phone call)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Minimal intervention (pharmacist case manager providing some level of communication)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 1000
Study: 16555577

Group type: EXPERIMENTAL
Intervention: Efonidipine (T‐ and L‐type Ca2+ channel blocker)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nifedipine (L‐type Ca2+ channel blocker)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Efonidipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Efonidipine and Nifedipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls (20 individuals)
Number of subjects: 40
Study: 12472980

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen gel (Ibugel) 5% applied for at least 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral ibuprofen 400 mg tablets (1200 mg daily) taken for at least 7 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen gel (Ibugel) 5%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral ibuprofen 400 mg tablets (1200 mg daily)
Number of subjects: 100
Study: 10528960

Group type: EXPERIMENTAL
Intervention: AM (herbal remedy)
Number of subjects: 88
Study: 8746878

Group type: EXPERIMENTAL
Intervention: Menorest 50
Number of subjects: 205

Group type: COMPARATOR
Intervention: Estraderm TTS 50
Number of subjects: 205
Study: 1778334

Group type: EXPERIMENTAL
Intervention: Lederle-Takeda APDT vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lederle DTP vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Takeda APDT vaccine
Number of subjects: 0
Study: 6168837

Group type: EXPERIMENTAL
Intervention: Perhexiline (100 mg twice daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31977740

Group type: EXPERIMENTAL
Intervention: Wireless oral patient-controlled analgesia device for the delivery of oxycodone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group receiving PRN oxycodone from nursing staff
Number of subjects: 30
Study: 31088856

Group type: EXPERIMENTAL
Intervention: Genetically predicted higher circulating alanine aminotransferase (ALT)
Number of subjects: 671106

Group type: EXPERIMENTAL
Intervention: Genetically predicted higher circulating aspartate aminotransferase (AST)
Number of subjects: 671106

Group type: EXPERIMENTAL
Intervention: Genetically predicted alkaline phosphatase (ALP)
Number of subjects: 671106

Group type: EXPERIMENTAL
Intervention: Genetically predicted γ‐glutamyl transferase (GGT)
Number of subjects: 671106

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to higher fasting insulin
Number of subjects: 671106
Study: 29075570

Group type: EXPERIMENTAL
Intervention: Transactional model education program (6 sessions over 2 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 25442646

Group type: EXPERIMENTAL
Intervention: Typical postoperative knee brace with adjustable range of motion (ROM) at 0° to 30°
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Typical postoperative knee brace with adjustable range of motion (ROM) at 0° to 60°
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Typical postoperative knee brace with adjustable range of motion (ROM) at 0° to 90°
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Typical postoperative knee brace with adjustable range of motion (ROM) at 20° to 90°
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (without a knee brace)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Other knee braces (patellofemoral realignment brace, ligament brace, valgus/osteoarthritis brace, elastic knee bandage)
Number of subjects: 64
Study: 24134898

Group type: EXPERIMENTAL
Intervention: Patient pain assessment using a 100‐mm visual analogue scale (VAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Provider pain assessment using a 100‐mm visual analogue scale (VAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Agreement on most painful time point of procedure
Number of subjects: 0
Study: 23040791

Group type: EXPERIMENTAL
Intervention: Mid-foot block (foot infiltration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sciatic nerve block (30mL of 7.5% ropivacaine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Mid-foot block and Sciatic nerve block)
Number of subjects: 40
Study: 19576082

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy scheme executed at day 1 and day 8 for 6 ‐ 8 cycles
Number of subjects: 62

Group type: COMPARATOR
Intervention: ABVD chemotherapy scheme executed at day 1 and day 15 for 6 ‐ 8 cycles
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 17381927

Group type: EXPERIMENTAL
Intervention: Weekly vitamin A supplementation
Number of subjects: 60
Study: 15041582

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Vitamin C, 500 mg)
Number of subjects: 60
Study: 11697443

Group type: EXPERIMENTAL
Intervention: Red wine (68 mg M-3-G)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (58 mg M-3-G)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Red grape juice (117 mg M-3-G)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Red wine and dealcoholized red wine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Red grape juice
Number of subjects: 6
Study: 9129483

Group type: EXPERIMENTAL
Intervention: Regular milk (240 mL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lactose-hydrolyzed milk (240 mL)
Number of subjects: 42
Study: 8199724

Group type: EXPERIMENTAL
Intervention: Felodipine (extended release) 5-20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enalapril 5-20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of felodipine and enalapril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 20
Study: 2901289

Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 66
Study: 31971474

Group type: EXPERIMENTAL
Intervention: Local heat therapy (HT) applied to one thigh (garment perfused with water at 52°C) for 8 consecutive weeks (90 min, 5 days/wk)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control thigh (no treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Local heat therapy (HT)
Number of subjects: 12
Study: 31157554

Group type: EXPERIMENTAL
Intervention: BUT 6 (BUT) strain
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Hybrid Converter (HYB) strain
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: HYB birds of both sexes
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Body lipid (g/100g bodyweight)
Number of subjects: 1680

Group type: EXPERIMENTAL
Intervention: Overall growth description
Number of subjects: 1680
Study: 28453299

Group type: EXPERIMENTAL
Intervention: LA-EP2006
Number of subjects: 174

Group type: COMPARATOR
Intervention: Reference pegfilgrastim
Number of subjects: 174
Study: 25476120

Group type: EXPERIMENTAL
Intervention: Drug use assessments
Number of subjects: 0
Study: 24070632

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine-75% alcohol solution for cutaneous antisepsis
Number of subjects: 834
Study: 21848781

Group type: EXPERIMENTAL
Intervention: 5-hour disaster training course
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 91
Study: 20066924

Group type: EXPERIMENTAL
Intervention: Simon task on color
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simon task on shape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simon task on orientation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simon task on color or shape
Number of subjects: 0
Study: 17215272

Group type: EXPERIMENTAL
Intervention: HIV prevention strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational epidemiology
Number of subjects: 0
Study: 15522126

Group type: EXPERIMENTAL
Intervention: Toast with butter (17.5 g fat)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cereal with full-fat milk (17.5 g fat)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cereal with semi-skimmed milk (2.7 g fat)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (0 g fat)
Number of subjects: 8
Study: 11996260

Group type: EXPERIMENTAL
Intervention: MIDCABG‐endo
Number of subjects: 190

Group type: COMPARATOR
Intervention: MIDCABG‐conv
Number of subjects: 190

Group type: COMPARATOR
Intervention: CABG‐conv
Number of subjects: 190
Study: 9709846

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 644
Study: 7913348

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine plus somatostatin
Number of subjects: 0
Study: 2573768

Group type: EXPERIMENTAL
Intervention: Subcutaneous catheter tunnelling (group B)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Traditional subclavian catheterisation (group A)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Contamination of the catheter hub
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Skin flora of nurses
Number of subjects: 109
Study: 1102987

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (50 mg twice daily) plus calcium carbonate (1 g four times daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31425170

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Remifentanil with dexmedetomidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Remifentanil
Number of subjects: 30
Study: 27632884

Group type: EXPERIMENTAL
Intervention: 40-Hz vibration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100-Hz vibration
Number of subjects: 10

Group type: COMPARATOR
Intervention: No vibration (control protocol)
Number of subjects: 10
Study: 26251666

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (OO)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 41
Study: 23758966

Group type: EXPERIMENTAL
Intervention: Self-reported MVPA
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Objectively measured MVPA
Number of subjects: 257
Study: 21233779

Group type: EXPERIMENTAL
Intervention: Foot orthoses (OR)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 99
Study: 19713092

Group type: EXPERIMENTAL
Intervention: Seal oil (SO), 10mL x 3 daily for 10 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Whale oil (WO), 10mL x 3 daily for 10 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Soy oil (control)
Number of subjects: 18
Study: 17597498

Group type: EXPERIMENTAL
Intervention: Cignolini methodology (Qigong massage)
Number of subjects: 13
Study: 15066805

Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides biscuits
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides biscuits
Number of subjects: 15
Study: 11570684

Group type: EXPERIMENTAL
Intervention: 10% polyacrylic acid (PAA) for 10 s, no rinsing
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10% PAA for 20 s, rinsed
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 25% PAA for 25 s, rinsed
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 32% phosphoric acid for 15 s, rinsed
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no acid pretreatment)
Number of subjects: 15
Study: 9768370

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone once daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matching placebo once daily for 12 weeks
Number of subjects: 30
Study: 7849541

Group type: EXPERIMENTAL
Intervention: Calcium intake Group 1 (409 +/‐ 21 mg calcium/day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Calcium intake Group 2 (663 +/‐ 16 mg calcium/day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Calcium intake Group 3 (950 +/‐ 32 mg calcium/day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Calcium intake Group 4 (1437 +/‐ 124 mg calcium/day)
Number of subjects: 55
Study: 2660862

Group type: EXPERIMENTAL
Intervention: Early consolidation with DATOP at lower dosage followed by maintenance chemotherapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone
Number of subjects: 203
Study: 1099598

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 20
Study: 31759132

Group type: EXPERIMENTAL
Intervention: Spine Explorer (automated segmentation and quantification program)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ImageJ (manual segmentation and quantification)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spine Explorer (automated measurements)
Number of subjects: 100
Study: 31021427

Group type: COMPARATOR
Intervention: 2008
Number of subjects: 24000

Group type: EXPERIMENTAL
Intervention: 2016
Number of subjects: 24000
Study: 28521838

Group type: EXPERIMENTAL
Intervention: Informed Healthcare Choices (IHC) primary school resources (textbook and teachers' guide), nine lessons of 80 minutes each covering 12 key concepts.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Current primary school curriculum (control group).
Number of subjects: 120
Study: 25853139

Group type: EXPERIMENTAL
Intervention: Specific strength training (SST)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: General fitness training (GFT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Health information (REF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy controls (CON)
Number of subjects: 41
Study: 21884028

Group type: EXPERIMENTAL
Intervention: Erythropoietin stimulating agents (ESA) - epoetin alfa
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 21522071

Group type: EXPERIMENTAL
Intervention: Midthigh power clean
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Midthigh clean pull
Number of subjects: 11

Group type: COMPARATOR
Intervention: Power clean
Number of subjects: 11

Group type: COMPARATOR
Intervention: Hang-power clean
Number of subjects: 11
Study: 18264870

Group type: EXPERIMENTAL
Intervention: Recruitment strategies for RCTs in drug and alcohol treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to patient participation
Number of subjects: 0
Study: 17199193

Group type: EXPERIMENTAL
Intervention: Liposomal eye spray (Tears Again)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Eye gel containing triglycerides (Liposic)
Number of subjects: 74
Study: 15626589

Group type: EXPERIMENTAL
Intervention: Aspirin 50 mg daily for 5 consecutive days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (matched for sex, age, and cardiovascular risk factors)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Colorectal cancer patients (without aspirin)
Number of subjects: 10
Study: 12663271

Group type: EXPERIMENTAL
Intervention: PEG-OB (80 mg weekly for 46 days)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10052405

Group type: EXPERIMENTAL
Intervention: 8 microg/kg daily IL-10
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 microg/kg 3 times per week IL-10
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IL-10 treatment
Number of subjects: 10
Study: 7552793

Group type: EXPERIMENTAL
Intervention: Peri-operative nutritional support for at least 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 0
Study: 2150187

Group type: EXPERIMENTAL
Intervention: 300 mg etodolac twice a day
Number of subjects: 65

Group type: COMPARATOR
Intervention: 20 mg piroxicam once a day
Number of subjects: 65
Study: 7191309

Group type: EXPERIMENTAL
Intervention: 3 x 60 mg acemetacin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31665115

Group type: EXPERIMENTAL
Intervention: PEG precipitation procedure
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cobas® immunoassay
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Architect i2000® immunoassay
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Size‐exclusion chromatography (SEC)
Number of subjects: 62
Study: 30593268

Group type: EXPERIMENTAL
Intervention: Delayed-start GnRH antagonist protocol with estrogen priming followed by early follicular-phase GnRH antagonist treatment for 7 days before ovarian stimulation with gonadotropin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard GnRH antagonist protocol with estrogen priming
Number of subjects: 120
Study: 26394294

Group type: EXPERIMENTAL
Intervention: Individualized education and mentored problem‐solving intervention via up to 10 telephone calls at 2‐week intervals.
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 153
Study: 25317794

Group type: EXPERIMENTAL
Intervention: Chronic asthma patients (Group A and Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 42
Study: 22983600

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Present-centered therapy
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Participants who no longer met diagnostic criteria for PTSD
Number of subjects: 218
Study: 20571434

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg over a 14-day period)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18717374

Group type: EXPERIMENTAL
Intervention: All-ceramic restorations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Porcelain-fused-to-metal (PFM) restorations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of MT(Implant) and MT(Tooth) values
Number of subjects: 30
Study: 16582545

Group type: EXPERIMENTAL
Intervention: Mg-rich mineral water (281 mg/l)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mg-rich mineral water (120 mg/l)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low mineralized water (8 mg/l)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mg capsule (Magnesium‐Diasporal 150)
Number of subjects: 22
Study: 15006256

Group type: EXPERIMENTAL
Intervention: RLX + low‐dose transdermal estrogen (RLX + E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: RLX + placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All subjects (combined)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phase II to Phase IV
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phase II
Number of subjects: 60
Study: 14674213

Group type: EXPERIMENTAL
Intervention: Urine antigen assays (EIA) for symptomatic men
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Urine antigen assays (EIA) for asymptomatic men
Number of subjects: 606
Study: 8826517

Group type: EXPERIMENTAL
Intervention: Intravenous sufentanil 1 microgram/kg given 5 min before induction of anaesthesia (group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intravenous sufentanil 1 microgram/kg given after ligation of the round ligaments of the uterus (group B)
Number of subjects: 39
Study: 1421710

Group type: EXPERIMENTAL
Intervention: Early high dose chemotherapy and autologous bone marrow transplantation (ABMT) rescue
Number of subjects: 28
Study: 6607596

Group type: EXPERIMENTAL
Intervention: Standard preparation (24 hr of clear liquids plus two major laxatives plus tap-water enemas)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colimmac lavage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colimmac lavage plus one major laxative
Number of subjects: 0
Study: 28862032

Group type: COMPARATOR
Intervention: No heparin pre-treatment (Control)
Number of subjects: 7144
Study: 29573941

Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib (oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Vemurafenib (oral vemurafenib 960 mg twice daily)
Number of subjects: 577

Group type: COMPARATOR
Intervention: Encorafenib (oral encorafenib 300 mg once daily)
Number of subjects: 577
Study: 26701234

Group type: EXPERIMENTAL
Intervention: 350 mg I/mL iodine concentration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 400 mg I/mL iodine concentration
Number of subjects: 50
Study: 24586292

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) administration
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22

Group type: COMPARATOR
Intervention: Children with CF (without LGG)
Number of subjects: 22
Study: 23086791

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 158
Study: 21038410

Group type: EXPERIMENTAL
Intervention: PEG IFN‐α2a 180 μg subcutaneously weekly and weight‐based oral RBV 800 to 1,200 mg daily for 24 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEG IFN‐α2a 180 μg subcutaneously weekly and weight‐based oral RBV 800 to 1,200 mg daily for 48 weeks
Number of subjects: 60
Study: 18845650

Group type: EXPERIMENTAL
Intervention: 2 units of oxytocin
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5 units of oxytocin
Number of subjects: 80
Study: 15836749

Group type: EXPERIMENTAL
Intervention: In-home educational intervention by peer health educators
Number of subjects: 150
Study: 12581832

Group type: EXPERIMENTAL
Intervention: Whole practice (practiced both parts of the 2:3 polyrhythm with pacing metronome tones)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Part practice (practiced each rhythm separately with corresponding pacing tone)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Part/whole practice (practiced each rhythm separately with pacing tones for both rhythms)
Number of subjects: 36